20:06 , Jun 19, 2019 |  BC Innovations  |  Distillery Therapeutics

HAS2 and NOTCH1 identified as targets in liver fibrosis induced by hepatitis B, hepatitis C and NASH

DISEASE CATEGORY: Hepatic INDICATION: Liver fibrosis; non-alcoholic steatohepatitis (NASH) Blocking hyaluronan synthesis, including via inhibition of HAS2 or its downstream effector NOTCH1, could help treat liver fibrosis. In hepatitis B, hepatitis C and NASH patients,...
18:01 , Mar 13, 2019 |  BC Innovations  |  Distillery Therapeutics

Inhibiting CARD9 for colitis and Crohn's disease

DISEASE CATEGORY: Gastrointestinal; autoimmune disease INDICATION: Colitis; Crohn's disease Patient sample and mouse studies suggest inhibiting CARD9 could help treat colitis and Crohn's disease. In water lavage samples from Crohn's disease patients, the numbers of...
02:35 , Feb 26, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Bladder cancer; breast cancer; colorectal cancer; melanoma; sarcoma Mouse studies suggest inhibiting DDR2 could enhance the efficacy of anti-PD-1 therapies for bladder, breast and colorectal cancers, melanoma and sarcoma. In mouse models of bladder...
23:17 , Oct 3, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: September 2018

New Therapeutic Targets and Biomarkers: September 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database in September. Therapeutic targets are defined as any protein, gene or other molecule...
17:35 , Sep 26, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Prostate cancer Patient sample and mouse studies suggest inhibiting glutamine uptake in cancer-associated prostate fibroblasts could help treat prostate cancers resistant to androgen receptor antagonists. In prostate cancer patients, high plasma levels of glutamine...
15:23 , Sep 20, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Cervical cancer, esophageal cancer, head and neck cancer, lung cancer Cell culture and mouse studies suggest inhibiting the long non-coding RNA (lncRNA) CCAT1 could help treat squamous cell carcinoma (SCC) of the cervix, esophagus,...
02:02 , Jun 9, 2018 |  BioCentury  |  Product Development

POC for cytokines

A body of clinical evidence is emerging that two different approaches to immune-stimulating cytokine therapies could increase efficacy of PD-1 inhibitors in both hot and cold tumors. Oncologists who spoke to BioCentury said, taken together,...
05:50 , Jun 2, 2018 |  BioCentury  |  Product Development

Breaking from the herd

Behind the block of clinical studies on PD-1 and PD-L1 inhibitors, researchers are casting aside their herd mentality with a wide net of strategies to solve some of the most pressing problems in oncology, such...
00:54 , Mar 10, 2018 |  BioCentury  |  Product Development

Defining progress

Erleada apalutamide’s landmark approval established a new primary endpoint in prostate cancer that shortens the time it takes to run the trials by up to five years, and paves the way for treating disease before...
20:36 , Feb 23, 2018 |  BC Week In Review  |  Company News

Organ-on-Chip company Emulate reveals new deals

Emulate Inc. (Cambridge, Mass.) announced partnerships with Roche (SIX:ROG; OTCQX:RHHBY) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) on Feb. 20, as well as an initiative with Cedars-Sinai Medical Center (Los Angeles, Calif.). The company's Organs-on-Chips are...